Skye Bioscience (SKYE) Accumulated Expenses (2012 - 2026)
Skye Bioscience (SKYE) posted quarterly Accumulated Expenses of $234392.0 for Q1 2026, down 64.28% year-over-year from $656131.0 in Q1 2025, and down 81.54% quarter-over-quarter from $1.3 million in Q4 2025.
Skye Bioscience (SKYE) Accumulated Expenses (2012 - 2026) Analysis & Trends
Skye Bioscience (SKYE) has reported Accumulated Expenses for 15 consecutive years, with $234392.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Accumulated Expenses fell 64.28% year-over-year to $234392.0; the TTM figure through Mar 2026 stood at $234392.0 (down 64.28% YoY), while the FY2025 annual figure was $1.3 million, up 13.93% from the prior year.
- Accumulated Expenses fell to $234392.0 in Q1 2026 per SKYE's latest filing, from $1.3 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $1.3 million in Q4 2025 and bottomed at $234392.0 in Q1 2026.
- Historically, Accumulated Expenses has averaged $681420.7 across 5 years, with a median of $656932.5 in 2022.
- Annual changes were most pronounced in 2023 — Accumulated Expenses jumped 234.34% — and 2026, when it sank 64.28%.
- Skye Bioscience's Accumulated Expenses stood at $657734.0 in 2022, then surged by 35.07% to $888381.0 in 2023, then rose by 25.43% to $1.1 million in 2024, then climbed by 13.93% to $1.3 million in 2025, then sank by 81.54% to $234392.0 in 2026.
- Business Quant data shows SKYE's Accumulated Expenses at $234392.0 in Q1 2026, $1.3 million in Q4 2025, and $920774.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Skye Bioscience | 10.86 Mn | 10.86 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 234,392.00 |
| Dec 31, 2025 | 1.27 Mn |
| Sep 30, 2025 | 920,774.00 |
| Jun 30, 2025 | 868,024.00 |
| Mar 31, 2025 | 656,131.00 |
| Dec 31, 2024 | 1.11 Mn |
| Jun 30, 2024 | 556,573.00 |
| Mar 31, 2024 | 353,462.00 |
| Dec 31, 2023 | 888,381.00 |
| Sep 30, 2023 | 645,830.00 |
| Jun 30, 2023 | 913,932.00 |
| Mar 31, 2023 | 792,501.00 |
| Dec 31, 2022 | 657,734.00 |
| Sep 30, 2022 | 443,983.00 |
| Jun 30, 2022 | 350,248.00 |
| Mar 31, 2022 | 237,037.00 |
| Dec 31, 2021 | 344,450.00 |
| Sep 30, 2021 | 262,881.00 |
| Jun 30, 2021 | 112,507.00 |
| Mar 31, 2021 | 131,995.00 |